ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD).

Dahshan Hassan Selim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.